Compare JKHY & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JKHY | IMVT |
|---|---|---|
| Founded | 1976 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.0B |
| IPO Year | 2000 | 2019 |
| Metric | JKHY | IMVT |
|---|---|---|
| Price | $150.13 | $39.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $197.25 | $33.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 19.31 | N/A |
| EPS | ★ 5.41 | N/A |
| Revenue | ★ $1,536,603,000.00 | N/A |
| Revenue This Year | $8.03 | N/A |
| Revenue Next Year | $6.39 | N/A |
| P/E Ratio | $27.40 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $121.04 | $14.32 |
| 52 Week High | $193.39 | $41.23 |
| Indicator | JKHY | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 55.86 |
| Support Level | $146.92 | $37.53 |
| Resistance Level | $157.87 | $41.23 |
| Average True Range (ATR) | 4.46 | 1.48 |
| MACD | -0.13 | -0.34 |
| Stochastic Oscillator | 57.92 | 41.08 |
Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.